Abstract
Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.
| Original language | English |
|---|---|
| Pages (from-to) | 177-183 |
| Number of pages | 7 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 103 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 1 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Adjuvant chemotherapy
- CMF chemotherapy
- Male breast cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
A prospective study of adjuvant CMF in males with node positive breast cancer : 20-Year follow-up. / Walshe, Janice M.; Berman, Arlene W.; Vatas, Ujala; Steinberg, Seth M.; Anderson, William F.; Lippman, Marc E; Swain, Sandra M.
In: Breast Cancer Research and Treatment, Vol. 103, No. 2, 01.06.2007, p. 177-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A prospective study of adjuvant CMF in males with node positive breast cancer
T2 - 20-Year follow-up
AU - Walshe, Janice M.
AU - Berman, Arlene W.
AU - Vatas, Ujala
AU - Steinberg, Seth M.
AU - Anderson, William F.
AU - Lippman, Marc E
AU - Swain, Sandra M.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.
AB - Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.
KW - Adjuvant chemotherapy
KW - CMF chemotherapy
KW - Male breast cancer
UR - http://www.scopus.com/inward/record.url?scp=34249053878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249053878&partnerID=8YFLogxK
U2 - 10.1007/s10549-006-9363-0
DO - 10.1007/s10549-006-9363-0
M3 - Article
C2 - 17039267
AN - SCOPUS:34249053878
VL - 103
SP - 177
EP - 183
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 2
ER -